This week, Trump announced a multi-million contract with Phlow Corporation, based in Richmond, Virginia, to begin returning pharmaceutical production to the U.S.
“This is a great day for America,” White House trade adviser Peter Navarro said of the move. “This has all of the elements of the Trump strategy. It’s made in the USA. It’s innovation that will allow American workers to compete with the pollution havens, sweatshops, and tax havens of the world.”
In an online conference, reported by Reuters, Chamber of Commerce CEO Tom Donohue said the U.S. must not re-shore all of its production back to America and must stay reliant on foreign supply chains. “Protecting the resiliency of our supply chain doesn’t have to mean re-shoring all production in the United States,” Donohue said.
Donohue said there will “continue to be a huge place in the U.S. economy for a global supply chain.” The U.S. has suffered from a shortage of vital drugs, rubber gloves, and plastic bottles due to decades-long free trade policies. The plurality of these basic necessities are made in China.
Research by the Coalition for a Prosperous America (CPA) has revealed that reshoring all pharmaceutical production to the U.S. would create more than 800,000 American jobs. Likewise, re-shoring all medical supplies to the U.S. has the potential to create more than 300,000 American jobs.
For years, economic nationalists have urged the Trump administration to make permanent its 25 percent tariffs on billions of Chinese imports. CPA economists have said that a permanent 25 percent tariff on all Chinese imports would bring a million jobs back to the U.S. by 2024.